From: The management of severe hypertension in Australian general practice
Total | New or changes in antihypertensive drugs | p-value (χ2 test) | |||||
---|---|---|---|---|---|---|---|
No | Yes | ||||||
Sample size | 6,416 | (100%) | 1,018 | (100%) | 5,398 | (100%) | |
Hypertension | 2,907 | (45.3%) | 436 | (42.8%) | 2,471 | (45.8%) | 0.08 |
Severe (SHT) | 254 | (4.0%) | 51 | (5.0%) | 203 | (3.8%) | 0.06 |
Normotension | 2,876 | (44.8%) | 261 | (25.6%) | (25.6%) 2,615 | (48.4%) | <0.0001 |
Unsustained | 1,884 | (29.3%) | 101 | (9.9%) | 1,783 | (33.0%) | <0.0001 |
Sustained | 404 | (6.3%) | 33 | (3.2%) | 371 | (6.9%) | <0.0001 |
Unknown | 588 | (9.2%) | 127 | (12.5%) | 461 | (8.5%) | <0.0001 |
Unknown BP | 633 | (9.9%) | 321 | (31.6%) | 312 | (5.8%) | <0.0001 |